Mirtin (Mirtazapine)

Mirtazapine, the active ingredient in Mirtin, is a tetracyclic antidepressant (NaSSA) presented as an oral tablet for oral use. It is prescribed to treat major depressive disorder in adult patients, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides reliable global distribution.

Mirtazapine is indicated for depressive disorders, acting on central neurotransmitter pathways to alleviate symptoms.

Major depressive disorder: reduces depressive symptoms and improves functional outcomes in adults. Depressive episodes in bipolar disorder (adjunct): may be used under specialist supervision to manage depressive phases. Depression with insomnia: helps improve sleep quality while treating depressive symptoms.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Serotonin syndrome, especially with other serotonergic agents - Suicidal ideation or worsening depression - Severe hepatic dysfunction - Hypotensive crisis

When prescribing Mirtin, clinicians should observe several safety considerations.

Assess hepatic function: evaluate liver enzymes before initiating therapy. Monitor for worsening depression or suicidal thoughts: especially during the first weeks of treatment. Consider sedation risk: advise patients not to operate machinery until they know how the drug affects them. Review concomitant CNS depressants: adjust doses to avoid excessive sedation. Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): may precipitate serotonin toxicity. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): can markedly reduce mirtazapine levels.

Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression and increased sedation. - CNS depressants (e.g., benzodiazepines, antihistamines): may enhance drowsiness. - Warfarin: potential alteration of INR, requiring closer monitoring.